Taken together, our data have suggested that gefitinib-induced STAT3 activation and subsequent Akt recovery may act as a novel mechanism of primary and possibly acquired resistance against gefitinib in NSCLC. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.